Our present results demonstrated that tamoxifen, fulvestrant, and anastrozole were effective against breast cancer cells regardless of ER-α and ER-β expression status, even if the mechanism of action is different for each endocrine therapy agent. This evidence concerns the gene ESR2 and breast cancer.